Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore
Research To Practice | Oncology Videos · Dr. Neil Love
February 9, 202654m 57s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Kathleen N Moore, including the following topics:
- Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
- Comparing toxicities of conventional chemotherapy and ADCs (6:26)
- Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
- Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
- Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
- Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
- Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)